Compare STRA & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STRA | NTLA |
|---|---|---|
| Founded | 2017 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.5B |
| IPO Year | 1996 | 2016 |
| Metric | STRA | NTLA |
|---|---|---|
| Price | $78.67 | $14.10 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 18 |
| Target Price | ★ $96.50 | $18.34 |
| AVG Volume (30 Days) | 220.2K | ★ 3.3M |
| Earning Date | 01-01-0001 | 05-21-2026 |
| Dividend Yield | ★ 3.16% | N/A |
| EPS Growth | ★ 60.48 | 3.14 |
| EPS | ★ 3.76 | N/A |
| Revenue | ★ $997,137,000.00 | $57,877,000.00 |
| Revenue This Year | $5.99 | $1.71 |
| Revenue Next Year | $3.79 | N/A |
| P/E Ratio | $20.21 | ★ N/A |
| Revenue Growth | 57.23 | ★ 59.55 |
| 52 Week Low | $72.17 | $5.90 |
| 52 Week High | $92.98 | $28.24 |
| Indicator | STRA | NTLA |
|---|---|---|
| Relative Strength Index (RSI) | 49.25 | 62.28 |
| Support Level | $73.81 | $10.44 |
| Resistance Level | $81.59 | $14.61 |
| Average True Range (ATR) | 2.67 | 0.79 |
| MACD | -0.02 | 0.10 |
| Stochastic Oscillator | 66.70 | 98.97 |
Strategic Education Inc. is an education services company that provides access to high-quality education through campus-based and online post-secondary education offerings, as well as through programs to develop job-ready skills for high-demand markets. The company operates through wholly-owned subsidiaries Strayer University and Capella University, both accredited post-secondary institutions of higher education located in the United States, as well as Torrens University, an accredited post-secondary institution of higher education located in Australia. It provide employees with access to affordable and industry relevant training, certificate, and degree programs. The reportable segments of the company are U.S. Higher Education, Australia/New Zealand and Education Technology Services.
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.